Marksans Pharma Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company continues to remain debt-free as of December 31, 2025, with a cash balance of INR 824.2 crores. - Management discussed using existing cash flows for operations and acquisitions, particularly in Europe, indicating no immediate need for external funding. - They are exploring acquisitions, but funding for these may come from available cash rather than new debt or equity. - Operating leverage and internal cash generation seem to be the focus for growth, reducing the likelihood of new fundraising in the near term.

- Regular capex is around INR 50-60 crores, mainly for optimizations. - A new manufacturing plant or block would trigger a larger capex of INR 150-200 crores, subject to order book and demand. - Current utilization of the Goa facility is about 50%, so significant hiring occurred there; employee cost is expected to normalize as utilization improves. - No immediate trigger to invest in a new block yet. - The Teva facility is contributing positively with revenues trending INR 560-600 crores, targeting INR 800 crores, aiding operating leverage. - Management is actively exploring acquisitions in Europe and Canada as strategic investments to accelerate growth in these regions. - Expected acquisitions in Europe within 2026 to two targets of variable size; no specific amount disclosed yet. - Cash of INR 824 crores available across subsidiaries for investment. - Overall, capex related to expansion and strategic M&A will be aligned with order book growth and geographic expansion plans.

- U.S. Market: - Order book strong at $220 million+, expecting ~20% growth in the upcoming financial year. - Growth seen despite geopolitical uncertainties in 2025, with optimism returning post trade deal. - New product launches expected to drive revenue; operating leverage visible from Teva facility. - Order book revenues (commercialization lag of ~5-6 months) to reflect more in next financial year. - U.K. Market: - Price erosion stabilizing; seasonal factors and new product filings (~4-5 products/month) expected to support growth. - Expecting healthy quarter-on-quarter growth in Q4 FY26. - New products have higher margins, expected to improve profitability over 18-24 months. - Europe & Canada: - Operations recently started; contribution expected over next 3-5 years. - Exploring M&As in Europe, with two acquisitions targeted, adding to growth. - Overall: - Targeting INR 4,000 crores revenue milestone in 2-3 years (FY28/29). - R&D to sales ratio likely to be 2.5%-3% to sustain new product pipeline. - Employee costs expected to normalize as Goa facility utilization increases.

- The company aims to achieve INR 4,000 crores revenue milestone in the next 2-3 years (by FY28 or FY29), with INR 5,000 crores targeted thereafter. - U.S. business expected to grow at around 20% in the upcoming financial year, supported by a strong $220 million+ order book and improving market conditions. - New product launches in the U.K. with higher margins are expected to improve profitability over 18-24 months once market dynamics stabilize. - Europe expansion, including acquisitions, anticipated to be a significant growth driver from 2026 onwards, although timelines and deal sizes remain uncertain. - Operating leverage is improving, especially from the Teva facility ramp-up, positively impacting EBITDA margins, which expanded to 21.3% in Q3 FY26. - R&D investment around 2.5%-3% of sales is expected to continue, supporting new product development and future growth. - Employee cost as a percentage of revenue is expected to normalize by Q2 FY27, potentially improving margin profile further. - Overall, management is optimistic about sustained revenue growth, margin expansion, and earnings improvement over the next 2-3 years.

- Current order book stands at over $220 million, primarily for the U.S. market. - Previous order book figures were around $180-190 million and have grown to $220 million. - The $220 million order book is expected to translate into revenue mainly in the next financial year, with a 5-6 month lag from order award to commercialization. - The company aims for a $300 million order book in the U.S. by FY28. - The order book relates mainly to the U.S., where the company expects strong growth. - Growth from this order book is expected to help achieve revenue milestones of INR 4,000 crores in the next 2-3 years. - Pending orders visibility from European acquisitions is uncertain and depends on deals closed, with discussions ongoing.